clarifying the mechanism of egfr inhibition in kras g13d colorectal cancer
Published 3 years ago • 4.7K plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
2:03
signaling pathways in intestinal homeostasis and colorectal cancer kras at centre stage
-
4:00
optimizing treatment with egfr inhibitors in colorectal cancer
-
0:15
colon cancer and egfr inhibitors
-
8:37
egfr mechanisms of resistance
-
2:17
sotorasib plus panitumumab in kras-mutated colorectal cancer | nejm
-
4:15
egfr in metastatic colon cancer
-
1:33
acquired resistance to anti-egfr therapy in colorectal cancer
-
24:33
molecular markers beyond kras for anti-egfr targeted agents — what is new?
-
14:39
egfr family and cancer
-
1:50
functional effects of ephb1 mutations in colorectal cancer
-
21:13
the kras variant and cancer risk
-
27:37
next generation egfr inhibitors for mutations and disease
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
1:46
inhibiting braf/egfr/mek for colorectal cancer | oncotarget
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
4:16
aacr 2009: genetic influences in response to egfr for metastatic colorectal cancer
-
5:09
egfr therapy as upfront colorectal cancer treatment
-
1:42
the cytokine protein ccl7 promotes bone metastasis from colorectal cancer